Systematic Reviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Aug 15, 2021; 12(8): 1325-1362
Published online Aug 15, 2021. doi: 10.4239/wjd.v12.i8.1325
What can we learn from β-cell failure biomarker application in diabetes in childhood? A systematic review
María F Calderón-Hernández, Nelly F Altamirano-Bustamante, Cristina Revilla-Monsalve, María Belen Mosquera-Andrade, Myriam M Altamirano-Bustamante
María F Calderón-Hernández, Cristina Revilla-Monsalve, Myriam M Altamirano-Bustamante, Unidad de Investigación en Enfermedades Metabólicas, Centro Médico Nacional Siglo XXI, IMSS, Mexico 06720, Mexico
Nelly F Altamirano-Bustamante, María Belen Mosquera-Andrade, Department of Endocrinology, Instituto Nacional de Pediatría, Mexico 04530, Mexico
Author contributions: Altamirano-Bustamante MM and Altamirano-Bustamante NF designed the research; Calderón-Hernández MF and Altamirano-Bustamante MM performed the research; Calderón-Hernández MF, Altamirano-Bustamante NF, Mosquera-Andrade MB, Revilla-Monsalve C and Altamirano-Bustamante MM analyzed the data; Calderón-Hernández MF, Altamirano-Bustamante NF and Altamirano-Bustamante MM wrote the paper; Altamirano-Bustamante NF and Altamirano-Bustamante MM supervised the paper; all authors read and approved the final manuscript; Calderón-Hernández MF, Altamirano-Bustamante NF and Altamirano-Bustamante MM contributed equally to this work.
Supported by Mexico’s National Council of Science and Technology (CONACYT), No. SALUD-2010-C02-151942; and Institute of Science and Technology of Mexico City.
Conflict-of-interest statement: The authors have declared that no competing interest exist.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Myriam M Altamirano-Bustamante, MD, PhD, Academic Research, Research Scientist, Senior Scientist, Teacher, Unidad de Investigación en Enfermedades Metabólicas, Centro Médico Nacional Siglo XXI, IMSS, Avenida Cuauhtémoc 330, Mexico 06720, Mexico. myriamab@unam.mx
Received: January 28, 2021
Peer-review started: January 28, 2021
First decision: March 30, 2021
Revised: April 12, 2021
Accepted: July 6, 2021
Article in press: July 6, 2021
Published online: August 15, 2021
Core Tip

Core Tip: β-cell failure biomarkers have been an elusive task, and the searching of a molecule that will work as a biomarker and therapeutic target is a challenge. The data obtained in this study demonstrated that real human islet amyloid polypeptide amyloid oligomers could be used as a sensitive and specific marker for diabetes as a protein conformational disease.